Improving Plasmonic Photothermal Therapy of Lung Cancer Cells with Anti-EGFR Targeted Gold Nanorods.
EGFR-targeting
cancer therapy
gold nanorods
lung cancer
nanoparticles
photoacoustic imaging
photothermal therapy
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
03 Jul 2020
03 Jul 2020
Historique:
received:
12
06
2020
revised:
28
06
2020
accepted:
01
07
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
Lung cancer is a particularly difficult form of cancer to diagnose and treat, due largely to the inaccessibility of tumours and the limited available treatment options. The development of plasmonic gold nanoparticles has led to their potential use in a large range of disciplines, and they have shown promise for applications in this area. The ability to functionalise these nanoparticles to target to specific cancer types, when combined with minimally invasive therapies such as photothermal therapy, could improve long-term outcomes for lung cancer patients. Conventionally, continuous wave lasers are used to generate bulk heating enhanced by gold nanorods that have accumulated in the target region. However, there are potential negative side-effects of heat-induced cell death, such as the risk of damage to healthy tissue due to heat conducting to the surrounding environment, and the development of heat and drug resistance. In this study, the use of pulsed lasers for photothermal therapy was investigated and compared with continuous wave lasers for gold nanorods with a surface plasmon resonance at 850 nm, which were functionalised with anti-EGFR antibodies. Photothermal therapy was performed with both laser systems, on lung cancer cells (A549) in vitro populations incubated with untargeted and targeted nanorods. It was shown that the combination of pulse wave laser illumination of targeted nanoparticles produced a reduction of 93 % ± 13 % in the cell viability compared with control exposures, which demonstrates a possible application for minimally invasive therapies for lung cancer.
Identifiants
pubmed: 32635387
pii: nano10071307
doi: 10.3390/nano10071307
pmc: PMC7407807
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : UK Research and Innovation
ID : EP/S001069/1
Références
Nat Methods. 2016 Jul 28;13(8):639-50
pubmed: 27467727
Nanomedicine (Lond). 2013 Jun;8(6):903-19
pubmed: 22963234
ACS Nano. 2015 Jan 27;9(1):52-61
pubmed: 25493329
Cancer Lett. 2006 Jul 28;239(1):129-35
pubmed: 16198049
Opt Lett. 2010 Jul 1;35(13):2127-9
pubmed: 20596168
Oncotarget. 2017 Jan 10;8(2):2187-2196
pubmed: 27974695
J Nanopart Res. 2010 Sep;12(7):2313-2333
pubmed: 21170131
Lasers Surg Med. 2007 Oct;39(9):747-53
pubmed: 17960762
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Int J Mol Sci. 2018 Oct 25;19(11):
pubmed: 30366384
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
pubmed: 11597399
Methods Mol Biol. 2011;731:237-45
pubmed: 21516412
Radiology. 2013 Jun;267(3):932-40
pubmed: 23440319
J Control Release. 2016 Dec 28;244(Pt A):108-121
pubmed: 27871992
J Biophotonics. 2019 Oct;12(10):e201900082
pubmed: 31155855
Nat Mater. 2020 May;19(5):566-575
pubmed: 31932672
Chem Soc Rev. 2012 Feb 7;41(3):1191-217
pubmed: 21947414